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Objective: The aim of this study was to explore the relation between preoperative tumor
size based on magnetic resonance imaging (MRI) and the surgical pathologic staging pa-
rameters (deep myometrial invasion, cervical stroma invasion, and metastatic lymph nodes)
and to assess the prognostic impact of tumor size in endometrial carcinomas. Interobserver
variability for the different tumor size measurements was also assessed.
Methods/Materials: Preoperative pelvic MRI of 212 patients with histologically con-
firmed endometrial carcinomas was read independently by 3 radiologists. Maximum tumor
diameters were measured in 3 orthogonal planes (anteroposterior, transverse, and
craniocaudal planes [CC]), and tumor volumes were estimated. Tumor size was analyzed in
relation to surgical staging results and patient survival. The multivariate analyses were
adjusted for preoperative risk status based on endometrial biopsy. Intraclass correlation
coefficients and receiver operating characteristics curves for the different tumor measure-
ments were also calculated.
Results: Anteroposterior tumor diameter independently predicted deep myometrial inva-
sion (P G 0.001), whereas CC tumor diameter tended to independently predict lymph node
metastases (P = 0.06). Based on receiver operating characteristic curves, the following
tumor size cutoff values were identified: anteroposterior diameter greater than 2 cm pre-
dicted deep myometrial invasion (unadjusted odds ratio [OR], 12.4; P G 0.001; adjusted OR,
6.7; P G 0.001) and CC diameter greater than 4 cm predicted lymph node metastases
(unadjusted OR, 6.2; P G 0.001; adjusted OR, 4.9; P = 0.009). Large tumor size was as-
sociated with reduced progression/recurrence-free survival (P e 0.005 for all size
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parameters), and CC diameter had an independent impact on survival (adjusted hazards
ratio, 1.04; P = 0.009). The interobserver variability for the different size measurements was
very low (intraclass correlation coefficient, 0.78Y0.85).
Conclusions: Anteroposterior tumor diameter greater than 2 cm predicts deep myometrial
invasion, and CC tumor diameter greater than 4 cm predicts lymph node metastases. Tumor
size is a strong prognostic factor in endometrial carcinomas. Preoperative tumor mea-
surements based on MRI may potentially improve preoperative risk stratification models
and thus enable better tailored surgical treatment in endometrial cancer.
Key Words: Endometrial carcinoma, Tumor size, Magnetic resonance imaging,
Prognosis
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Endometrial cancer is the most common gynecologic ma-lignancy in industrialized countries, and the incidence is
increasing.1 Surgical treatment is planned based on preop-
erative assessment of histological subtype, grade, and depth
of myometrial invasion. Surgical International Federation of
Gynecology and Obstetrics (FIGO) stage is documented to be
the strongest prognostic factor in endometrial carcinoma, thus
guiding adjuvant therapy in addition to the assessment of his-
tologic subtype and grade in the hysterectomy specimen.1Y3
Magnetic resonance imaging (MRI) has long been con-
sidered the diagnostic imaging method of choice for preoper-
ative staging of endometrial carcinomas.4Y6 The presence of
deepmyometrial invasion and cervical stroma invasion could be
visualized, and enlarged lymph nodes could be detected.
However, conventional pelvicMRIhas reportedly limitations in
accuracy in the detection of the staging parameters, in particular
for detecting lymph node metastases.6,7 Interobserver variation
between radiologists for all staging parameters also represents a
source of inaccuracy.8
As opposed to the cervical cancer FIGO staging system,6
FIGO staging for endometrial cancers does not include tumor
size measurements. Nevertheless, large macroscopic tumor
size, assessed in the hysterectomy specimen, has long been
known to predict lymph node metastasis and poor survival in
patients with endometrial carcinomas.9Y13 Recent publications
support that tumor volume based on preoperativeMRI predicts
lymph node metastases and has prognostic impact in endo-
metrial cancer.14,15 However, the reproducibility of MRI-based
tumor measurements has, to our knowledge, not yet been ex-
plored. Furthermore, the optimal cutoff value for risk assess-
ment based on tumor size is not yet defined.
The primary objective of this study was to explore the
relationship between different preoperative tumor size mea-
surements using MRI and the surgical pathologic staging
parameters deep myometrial invasion, cervical stroma inva-
sion, and metastatic lymph nodes in endometrial carcinoma
patients. The secondary objectives were to assess the inter-
observer variability for the different tumor measurements and
to explore the value of these preoperative tumor size mea-
surements to identify patients with poor outcome.
MATERIALS AND METHODS
Patient Series, Study Setting,
and Clinical Outcome
This prospective study was conducted under institu-
tional review boardYapproved protocols with informed con-
sent from all patients. From April 2009 to November 2013,
preoperative pelvic MRI was performed in 212 patients in
whom the diagnosis of endometrial carcinoma was histo-
logically verified at surgical staging. All patients were diag-
nosed and treated at the same university hospital serving a
population of ~1 million inhabitants.
Follow-up data regarding recurrence, progression, and
survival have been collected from patient records and from
correspondence with the responsible primary physicians or
gynecologists. The date of the last follow-upwas July 2014, and
themean (range) follow-up for survivorswas25 (0Y58)months.
Histological Diagnosis
All patients were surgically staged according to the 2009
FIGO staging criteria.2 The responsible surgeon decided the
extent of sampling, balancing preoperatively known histologic
risk factors and the patient’s comorbidity. The patient group
without lymph node sampling is typically older with more
myometrial invasion, otherwise not different from the sampled
group.16 Surgical specimens were sectioned along the longi-
tudinal plane of the uterus, and myometrial invasion and cer-
vical stromal invasion were estimated grossly and confirmed
microscopically according to standard procedures.17 Routine
histopathology reports were generated without knowledge of
preoperative MRI findings. The pathologists documented
number and size of metastatic lymph nodes.
MRI Protocol
Contrast-enhanced (CE)MRI was performed on a 1.5-T
SiemensAvantoRunningSyngoMRB17 (Erlangen,Germany)
using a 6-channel body coil8 in accordance with the guidelines
of European Society of Urogenital Imaging.5 Themean (range)
interval between MRI examination and surgical staging was
11.3 (0Y98) days.
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Data Analysis
All images were deidentified and read independently by
3 observers who were blinded for tumor stage, histological
diagnosis, and patient outcome. Observer 1 and 2 are con-
sultants with more than 10 years of experience with pelvic
MRI. Observer 3 included 2 junior radiologists (both having
more than 4 years of experience with pelvic MRI); one read
the first 105 MRI examinations, and the other read the fol-
lowing 111 examinations.
All observers reported imaging findings on a stan-
dardized form. Presence of deep myometrial invasion (tumor
invading half or more of the myometrial wall), cervical stroma
invasion (disruption of the low-signal intensity cervical
stroma on T2-weighted images), and enlarged pelvic or para-
aortic lymph nodes (largest short-axis diameter 910mm)were
recorded. Maximum tumor diameters were measured in 3
orthogonal planes: anteroposterior (AP) and transverse (TV)
diameters on axial CE T1-weighted oblique images (per-
pendicular to the long axis of the uterus) as well as
craniocaudal (CC) diameters on sagittal T2-weighted images
(Fig. 1). Tumor volume was then estimated based on these
measurements of maximum tumor diameter in 3 orthogonal
planes using the following equation: tumor volume = AP
diameter  TV diameter  CC diameter/2.
To establish the overall imaging findings based on the
recordings by all 3 observers, we also computed a new data set
(‘‘consensus reading’’) in which the value given by the ma-
jority of the observers was recorded for categorical variables,
and the median value was recorded for continuous variables.
Statistical Analysis
Estimation of sample size was done by W2 test using
software East4 2005 (Cytel Software Corp). To achieve 90%
power of detecting a 20% higher occurrence of positive
markers in patients with metastatic lymph nodes (5% vs 25%)
at a 5% significance level, 101 patients were needed for in-
clusion, defining the minimum number of patients to be in-
cluded in theMRI study. To reach 90% power detecting a 30%
difference in 5-year survival (90% for patients with markers
within reference range vs 60% with pathologic markers) at a
5% level of significance, 65 patients were needed, assuming a
positive to negative ratio of the markers of 1:3.
Clinical and histopathology staging parameters were
analyzed in relation to tumor size measurements using Mann-
Whitney U test, Kruskal-Wallis H test, Jonckheere-Terpsta
trend test, W2 test, and binary logistic regression analysis.
Intraclass correlation coefficient was used to assess the
consistency and reproducibility of tumor size measurements,
and minimal detectable change (1.96  standard error of the
mean square root of 2) for the measured diameters was also
calculated.
Receiver operating characteristic (ROC) analysis was
performed to evaluate the diagnostic value of the different
tumor size measurements in identifying deep myometrial
invasion, cervical stroma invasion, and lymph node metas-
tases. The optimal cutoff values (rounded to centimeters) were
determined for which the best separation in Youden index
between groups was achieved.
Differences in time to recurrence (for patients consid-
ered cured by primary treatment) or progression (for patients
known to have residual disease after primary treatment) were
assessed by the Mantel-Cox (log-rank) linear trend test. The
Cox proportional hazards model was used to study the effect
on survival of continuous variables. The prognostic value of
different tumor size categories was explored with univariate
analyses using Kaplan-Meier, and groups with similar sur-
vival were merged. McNemar test was used for pairwise
analysis for differences in sensitivity, specificity, and accu-
racy. The data were analyzed using SPSS 22.0 (Chicago, IL)
and Stata 12.1 (College Station, TX). All reported P values
were 2-sided and considered to indicate statistical signifi-
cance when less than 0.05.
RESULTS
Patients
The median (mean) patient age in the study sample
(n = 212) was 66 (66) years (range, 32-93), and 91% (193/212)
of the patients were postmenopausal. Applying the FIGO
2009 staging criteria, 55% (116/212) were stage IA (G50%
FIGURE 1. Axial oblique CE T1-weighted image (A) and sagittal T2-weighted image (B) for measurements of
maximum tumor diameters in 3 orthogonal planes. AP and maximum TV diameters were measured on the axial
oblique image (A), whereas CC diameters were measured on the sagittal image (B).
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myometrial invasion), 23% (48/212) stage IB (Q50% myo-
metrial invasion), 11% (23/212) stage II (cervical stroma
invasion), 11% (24/212) stage III (local or regional tumor
spread), and 0% (1/212) stage IV. The histological subtype
was endometrioid in 81% (171/212) of which 50% (86/171)
were grade 1, 29% (50/171) grade 2, and 17% (29/171) grade
3; whereas 4% (6/171) were ungraded. Clear cell histology
was detected in 3% (6/212), serous in 10% (21/212), carci-
nosarcoma in 4% (9/212), and undifferentiated in 2% (5/212).
Metastatic lymph nodes were more frequent in patients with
deep myometrial invasion, cervical stroma invasion, high his-
tologic grade, aneuploidy, and body mass index (BMI) greater
than 25 (Table 1).
All patientswere primarily treatedwith hysterectomy and
bilateral salpingo-oophorectomy. Pelvic lymph node sampling
was performed in 85% (181/212) as part of the routine surgical
staging procedure. Adjuvant therapy was given to 33% (70/
212), chemotherapy in 28% (59/212), pelvic radiation in 5%
(10/212), and hormonal treatment in 0% (1/212).
Tumor Size Is Correlated to
Surgicopathologic Findings
The mean (median, range) preoperative tumor di-
ameters were 28 (26, 0Y113) mm for axial TV diameter, 18
(16, 0Y77) mm for axial AP diameter, and 35 (31, 0Y102) mm
for sagittal CC diameter. The mean (median, range) estimated
tumor volume was 19 (6, 0Y444) mL. Tumor volume was
significantly higher in patients with deep myometrial inva-
sion, cervical stroma invasion, and lymph node metastases at
surgical staging and in patients with aneuploidy and high
histologic grade (Table 2).
Tumor measurements in the 3 orthogonal planes and
tumor volume did all predict the presence of deep myometrial
invasion at surgical staging (unadjusted odds ratios [ORs],
1.06Y1.13; P G 0.001 for all); however, AP tumor diameter
was the only size variable independently predicting deep
myometrial invasion (adjusted OR, 1.14; P G 0.001).
Craniocaudal tumor diameter was the only variable predicting
cervical stroma invasion (adjusted OR, 1.04; P = 0.008).
Although all size parameters predicted lymph node metas-
tases in the univariate analyses (unadjusted ORs, 1.02Y1.05;
P e 0.004 for all), only CC tumor diameter tended to inde-
pendently predict lymph node metastases (adjusted OR, 1.04;
P = 0.06).
Receiver operator characteristic curves for the different
size parameters in the prediction of deep myometrial invasion
(Fig. 2A), cervical stroma invasion (Fig. 2B), and lymph node
metastases (Fig. 2C) showed that AP diameter had the highest
area under the curve (AUC, 0.82) for deepmyometrial invasion,
whereas CC diameter had the highest AUC for cervical stroma
invasion (AUC, 0.66) and for lymph node metastases (AUC,
0.76). Based on these ROC curves, the following cutoff values
were identified: AP tumor diameter greater than 2 cm predicts
deep myometrial invasion yielding sensitivity/specificity of
66%/86% and an OR of 12.4, and CC tumor diameter greater
than 4 cm predicts lymph node metastases yielding sensitivity/
specificity of 70%/73% and an OR of 6.2, whereas CC tumor
diameter greater than 3 cm tends to predict cervical stroma
invasion yielding sensitivity/specificity of 66%/51% and an
TABLE 1. Clinical characteristics and MRI findings in
relation to the presence of metastatic lymph nodes at
surgical staging in 181 endometrial carcinoma patients
Variable n
LN+ LNj
P*
n = 20 n = 161
n (%) n (%)
Low-risk group† 72 0 (0) 72 (46) G0.001
Intermediate-risk group† 51 10 (50) 41 (26)
High-risk group† 54 10 (50) 44 (28)
Myometrial invasion G 0.001
G50% 109 4 (20) 105 (65)
Q50% 72 16 (80) 56 (35)
Cervical stroma invasion 0.001
Yes 27 8 (40) 19 (12)
No 154 12 (60) 142 (88)
Histologic subtype 0.14
Endometrioid 141 13 (65) 128 (80)
Nonendometrioid 40 7 (35) 33 (20)
Histological grade among
endometrioid subtype
0.007
Grade 1 70 2 (15) 68 (55)
Grade 2 42 5 (38) 37 (30)
Grade 3 25 6 (46) 19 (15)
Ploidy 0.014
Diploid 77 6 (50) 71 (82)
Aneuploid 22 6 (50) 16 (18)
Age, y 0.10
G66 95 7 (35) 88 (54)
Q66 86 13 (65) 73 (45)
BMI 0.03
G25 66 3 (15) 63 (40)
Q25 113 17 (85) 96 (60)
Tumor size at MRI G0.001
AP e2 cm and/or
CC e4 cm
136 8 (40) 128 (80)
AP 92 cm and CC 94 cm 45 12 (60) 33 (20)
Enlarged lymph nodes
at MRI
G0.001
Enlarged lymph nodes 13 9 (45) 4 (2)
Normal lymph nodes 168 11 (55) 157 (98)
Significant P values are presented in boldface.
*W2 Test.
†Risk groups defined in European Society for Medical Oncology
guidelines26: low risk, endometrioid grade 1/2 with myometrial inva-
sion G50%; intermediate risk, endometrioid grade 1/2withmyometrial
invasion Q50% or endometrioid grade 3 with myometrial invasion G
50%; high risk, endometrioid grade 3 with myometrial invasion Q50%
or nonendometrioid histology
LN+, patients with lymph nodes metastases at surgical staging;
LNj, patients without lymph node metastases at surgical staging.
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OR of 2.0 (Table 3). When adjusting for risk status based on
preoperative endometrial biopsy and for conventional imaging
findings (consensus reading) suggesting deep myometrial
invasion, cervical stroma invasion, and lymph node metasta-
ses, respectively, AP diameter greater than 2 cm independently
predicted deep myometrial invasion (adjusted OR, 6.7), and
CC diameter greater than 4 cm independently predicted lymph
node metastases (adjusted OR, 4.9), whereas CC diameter
greater than 3 cm did not predict cervical stroma invasion
(Table 3).
Tumor Size Predicts Progression/
Recurrence-Free Survival
The 3 tumor diameter measurements and tumor volume
did all predict progression/recurrence-free survival (P e 0.01
for all size parameters) in endometrial carcinoma patients. In a
multivariate analysis including all size parameters and pre-
operative risk status based on endometrial biopsy, only CC
tumor diameter had an independent impact on survival (Table 4,
SupplementalDigital Content, http://links.lww.com/IGC/A270).
When stratifying patient groups according to the proposed
cutoff values for size variables defined by the ROC analyses,
patients with AP tumor diameter greater than 2 cm and patients
with CC tumor diameter greater than 4 cm had significantly
reduced progression/recurrence-free survival (P e 0.03 for
both; Figs. 3A, B). Combining these 2 size criteria yielded
similar survival curves among patients with both or 1 size
criterion below the cutoff values (the 2 survival curves are thus
merged in Fig. 3C), whereas patients with both AP tumor di-
ameter greater than 2 cm and CC tumor diameter greater than
4 cm had significantly reduced progression/recurrence-free
survival (P = 0.004; Fig. 3C).
Interobserver Variability for Tumor
Measurements
The interobserver variability for tumor diameter
measurements by the 3 observers was low with intraclass
correlation coefficients of 0.78 to 0.85 and minimum de-
tectable change of 14 to 26 mm for the different tumor di-
ameter measurements (Table 5, Supplemental Digital Content,
http://links.lww.com/IGC/A270). Furthermore, the AUCvalues
of the ROC curves for prediction of deep myometrial invasion,
cervical stroma invasion, and lymph node metastases were not
significantly different between observers (Figs. 2D-F).
DISCUSSION
In this large population-based study, we demonstrate a
significant predictive value of preoperative tumor size mea-
surements based on MRI to identify deep myometrial invasion
and lymph node metastases. Furthermore, tumor size had a
significant independent impact on survival alsowhen adjusting
for preoperative risk status based on endometrial biopsy. Based
on the present study, we propose a riskmodelwith cutoff values
of AP tumor diameter greater than 2 cm indicating high risk for
deep myometrial invasion and CC tumor diameter greater than
4 cm indicating high risk for lymph node metastases. Having
established that the interobserver variability for these different
tumor measurements at MRI was very low, we infer that these
preoperative tumor measurements with corresponding cutoff
values may represent robust biomarkers aiding in the preop-
erative risk stratification and in planning of tailored surgical
treatment in endometrial cancer patients.
Presence of deep myometrial invasion in hysterectomy
specimen at surgicopathological staging is associated with an
increased risk of lymph node metastases, tumor recurrence,
and distant relapse in endometrial carcinoma patients.3,18 We
found that all size parameters predicted deep myometrial
invasion, which is in accordance with the findings of Todo
et al14 reporting high volume indexes (defined as the product
TABLE 2. Tumor volume in relation to clinical and
histologic characteristics in 212 endometrial
carcinoma patients
Variable n
Tumor
Volume, mL
P*Mean (95% CI)
Myometrial invasion G0.001
G50% 132 7.4 (5.2Y9.7)
Q50% 80 37.5 (23.4Y51.6)
Cervical stroma invasion 0.049
Yes 32 33.7 (5.2Y62.2)
No 180 16.1 (11.4Y20.8)
Lymph node metastases G0.004
Yes 20 62.7 (12.0Y113.5)
No 161 13.9 (10.2Y17.6)
Histologic subtype 0.27
Endometrioid 171 13.4 (10.2Y16.6)
Clear cell 6 20.6 (0.0Y50.4)
Serous 21 21.0 (4.9Y37.1)
Carcinosarcoma 9 65.5 (0.0Y135.8)
Undifferentiated/others 5 107.8 (0.0Y345.6)
Histological grade among
endometrioid subtype
G0.001
Grade 1 86 8.9 (5.6Y12.1)
Grade 2 50 14.7 (9.4Y19.9)
Grade 3 29 26.5 (13.2Y39.8)
Ploidy 0.015
Diploid 91 24.7 (12.8Y36.7)
Aneuploid 23 41.1 (21.4Y60.7)
Age, y 0.21
G66 106 15.6 (7.0Y24.3)
Q66 106 22.0 (14.2Y29.8)
BMI 0.38
G25 74 15.1 (9.1Y21.1)
Q25 134 20.9 (12.4Y29.4)
Significant P values are presented in boldface.
*Mann-WhitneyU test for 2 categories and Kruskal-Wallis H test
or Jonckheere-Terpsta trend test for multiple categories.
CI, confidence interval.
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TABLE 3. Sensitivity, specificity, LR+, LRj, and OR for the prediction of deep myometrial invasion
(by AP tumor diameter 92 cm), cervical stroma invasion (by CC tumor diameter 93 cm), and lymph node
metastases (by CC diameter 94 cm) using surgical staging as the criterion standard
AP Tumor Diameter
92 cm and Deep
Myometrial Invasion
CC Tumor Diameter
93 cm and Cervical
Stroma Invasion
CC Tumor Diameter
94 cm and Lymph
Node Metastases
Sensitivity, % (positive/total no. patients) 66 (53/80) 66 (21/32) 70 (14/20)
Specificity, % (positive/total no. patients) 86 (114/132) 51 (91/180) 73 (117/161)
LR+ 4.9 1.5 2.6
LRj 0.39 0.68 0.41
Unadjusted and adjusted* OR (95% CI);
P value† for deep myometrial invasion/cervical
stroma invasion/lymph node metastases based
on size cutoff values
12.4 (6.3Y24.5) 2.0 (0.9Y4.3) 6.2 (2.2Y17.2)
P G 0.001 P = 0.10 P G 0.001
6.7 (3.1Y14.4) 1.1 (0.4Y2.7) 4.9 (1.5Y15.8)
P G 0.001 P = 0.85 P = 0.009
*Adjusted for risk status based on preoperative endometrial biopsy and conventional imaging findings (consensus reading) suggesting
deep myometrial invasion, cervical stroma invasion, and lymph node metastases, respectively.
†Binary logistic regression analysis.
LR+, likelihood ratio for positive results: LR+ = sensitivity/(1 j specificity); LRj, likelihood ratio for negative results: LRj =
(1 j sensitivity)/specificity.
FIGURE 2. Receiver operator characteristic curves for the various tumor size measurements for identification of (A)
deep myometrial invasion, (B) cervical stroma invasion, and (C) lymph node metastases and ROC curves for the
different observers for (D) AP diameter to predict deep myometrial invasion, (E) CC diameter to predict cervical
stroma invasion, and (F) CC diameter to predict lymph node metastases in patients with endometrial carcinoma.
P values refer to the test of equal AUC values across tumor measurements.
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of maximum AP, TV, and CC tumor diameters at MRI) to be
associated with deep myometrial invasion. As opposed to
Todo et al,14 we have also explored the independent impact of
the different size variables in a multivariate model including
preoperative risk status based on endometrial biopsy. Inter-
estingly, AP diameter, which had the largest AUC (Fig. 2A),
proved to be the only size variable independently predicting
deep myometrial invasion.
Based on the ROC curve, the optimal cutoff value for
prediction of deep myometrial invasion was AP diameter
greater than 2 cm, and AP diameter greater than 2 cm inde-
pendently predicted deep myometrial invasion even when
adjusting for conventional imaging findings (consensus
reading) suggesting the same. Interestingly, we found that
AP diameter greater than 2 cm and MRI indicating deep
myometrial invasion had comparable accuracy (sensitivity,
specificity) for identification of deep myometrial invasion at
surgical staging: 79% (66%, 86%) and 74% (70%, 77%),
respectively, however, with significantly better specificity for
AP diameter greater than 2 cm (86% vs 77%; P = 0.015,
McNemar test). Thus, this relatively simple approach of
measuring AP tumor diameter yields a diagnostic perfor-
mance similar to or slightly better than conventional reading
for prediction of deep myometrial invasion.
Several surgicopathological risk models for prediction
of lymph node metastases have been proposed in endometrial
cancer based on histologic grade, subtype, and tumor ex-
tent,10,19,20 among which 1 model includes tumor greater than
2 cm based on the gross inspection of hysterectomy speci-
men.10 These models are, however, limited by the fact that
they rely on surgicopathological staging results, which are per
definition not available preoperatively.
Tumor diameter greater than 2 cm in macroscopic fresh
tissue has been reported to independently predict lymph node
metastases and survival9; however, the independent impact on
survival of tumor size greater than 2 cm has not been consis-
tently reproduced in the literature.10,13 Based on macroscopic
gross inspection of the cut-up of the uterus, maximum tumor
dimension greater than 3.75 cm was recently reported an in-
dependent predictor of deep myometrial invasion, distant re-
currence, and death.11 Because CC diameter was almost
uniformly the largest tumor diameter in our study, our cutoff
value for CC diameter greater than 4 cm seems to be in linewith
the proposed cutoff value of 3.75 cm. Direct comparison be-
tween tumor diameter measurements in macroscopic fresh tis-
sue and preoperatively based on MRI is, however, difficult due
to the differences in planes eligible for tumormeasurements and
the potential distortion and compression of tumor tissue in vivo
compared with ex vivo. Thus, the optimal cutoff values for
tumor size are not necessarily transferable from in vivo MRI-
based assessment to the ex vivo gross section-based tumor
measurements. Still, the metastatic potential and unfavorable
prognostic impact of large tumor size in endometrial carcinomas
is consistently supported by both invivo and ex vivo studies.9Y15
We found that the MRI-based parameters AP tumor
diameter greater than 2 cm and CC tumor diameter greater
than 4 cm both alone and combined are strongly associated
with reduced progression/recurrence-free survival in endo-
metrial carcinomas (Fig. 3). These tumor size parameters
should in the future also be evaluated in relation to other
preoperative biomarkers such as p53, hormone receptor, and
DNA ploidy status in preoperative biopsies, prognostic
markers assessed in blood samples,21 and on functional im-
aging by MRI or PET/CT, which have been shown to yield
prognostic information.16,22Y25
For all risk stratification models, high accuracy and
reproducibility of the variables included in the model are
essential. To our knowledge, this is the first study assessing
the interobserver variability for the different tumor size
measurements at MRI in endometrial cancer. Interestingly, we
found that tumor size was measured with very low inter-
observer variability and with no striking difference related to
the readers’ previous experience. Thus, tumor size measure-
ments seem to represent robust biomarkers that are promising
for potential inclusion in future risk stratification models in
endometrial cancer.
FIGURE 3. Kaplan-Meier survival curves depicting progression/recurrence-free survival according to (A) maximal
AP tumor diameter (e2 vs 92 cm), (B) maximal CC tumor diameter (e4 vs 94 cm), and (C) a combination of AP
and CC tumor diameters (AP e2 cm and/or CC e4 cm vs AP 92 cm and CC 94 cm). P values refer to the log-rank
test for equality of survival distribution.
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This study has some limitations. First, the study was
conducted in a single institution using a standardized imaging
protocol. Thus, the potential impact of various imaging pro-
tocols on MRI-based tumor size measurements has not been
assessed. However, our imaging protocol is based on the
guidelines of the European Society of Urogenital Imaging and is
thus expected to be quite similar to those applied at most centers
treating endometrial cancer patients. Second, intraobserver
variability was not assessed in this study. This is, however,
expected to be lower than the observed interobserver variability,
which was very low in this study, and the intraobserver vari-
ability is thus expected to be almost negligible.
In summary, tumor size assessed preoperatively byMRI
predicts the presence of deep myometrial invasion and lymph
node metastases and is a strong prognostic factor in endo-
metrial carcinoma. Based on our findings, we propose cutoff
values greater than 2 cm AP tumor diameter for predicting
deep myometrial invasion and greater than 4 cm CC tumor
diameter for predicting lymph node metastases, as well as
poor survival for the combination of greater than 2 cmAP and
greater than 4 cm CC tumor diameter. Preoperative tumor
measurements at MRI may thus provide clinically relevant
biomarkers for future risk stratification models guiding tai-
lored surgical treatment in endometrial cancer.
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